The Company is committed to leveraging its products and services to establish a potential new standard of care across multiple malignant tumor applications.
The Company is a healthcare solution provider dedicated to the development and commercialization of brachytherapy TPS specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors.
FTTPS is technologically advanced and has a wide range of clinical indications. FTTPS is widely used in diseases caused by many types of malignant tumors, including but not limited to prostate cancer, lung cancer, pancreatic cancer, liver cancer, esophageal cancer, and breast cancer.
The Company offers personalized and inclusive services that catered to the specific requirements of its clients.
公司致力于利用我們的產(chǎn)品和服務(wù)，在多種惡性腫瘤應(yīng)用中建立潛在的新護(hù)理標(biāo)準(zhǔn)。
我們是一家醫(yī)療解決方案提供商，致力于開(kāi)發(fā)和商業(yè)化專(zhuān)門(mén)用于放射性粒籽植入的近距離治療計(jì)劃軟件，粒籽植入治療是一種通過(guò)在患者體內(nèi)放置放射源來(lái)殺死癌細(xì)胞和縮小腫瘤的治療癌癥患者的放射療法。
FTTPS技術(shù)先進(jìn)，具有廣泛的臨床適應(yīng)癥。FTTPS廣泛應(yīng)用于多種惡性腫瘤引起的疾病，包括但不限于前列腺癌、肺癌、胰腺癌、肝癌、食管癌、乳腺癌等。
公司提供根據(jù)客戶(hù)的具體要求提供個(gè)性化和包容性的服務(wù)。
The Company focuses on key growth strategies to realize its mission:
· Enhance ability to attract, incentivize and maintain good relationships with talented professionals. The Company believes its success greatly depends on the ability to attract, incentivize and maintain long-term relationships with talented professionals. In addition, the Company aims to keep long-term relationships with third-party development teams or experts.
· Continue to invest in research and development. The Company attributes part of its success to our continued investment in and focus on R&D.
The Company emphasizes quality control in all aspects of its operations to ensure its products meet stringent internal standards, international and industry standards, as well as detailed requirements of various laws and regulations relating to medical devices, including but not limited to the registration and filings for medical devices, the production and operation license, the production and quality management.
The TPS market is characterized by rapid product development, technological advances, intense competition and a strong emphasis on proprietary products. Across all product lines and product tiers, The Company faces direct competition both domestically in China and internationally. Factors such as price, value, customer support, brand recognition, reputation, and product functionality, reliability, and compatibility are key considerations in the competition.
As of 2023, Beijing Feitian holds a market share of 61.2% in terms of the total number of installed brachytherapy TPS in the market.
The Company’s mission is to provide innovative healthcare solutions and world-class service to become a reliable partner with hospitals, physicians and patients.
公司專(zhuān)注于關(guān)鍵發(fā)展戰(zhàn)略以實(shí)現(xiàn)其使命：
· 提高吸引、激勵(lì)人才并與之保持良好關(guān)系的能力。公司相信其成功在很大程度上取決于吸引、激勵(lì)和保持與有才能的專(zhuān)業(yè)人士的長(zhǎng)期關(guān)系的能力。此外，公司旨在與第三方開(kāi)發(fā)團(tuán)隊(duì)或?qū)＜冶３珠L(zhǎng)期合作關(guān)系。
· 持續(xù)投資研究開(kāi)發(fā)。公司的成功部分歸功于其對(duì)研發(fā)的持續(xù)投資和專(zhuān)注。
公司在經(jīng)營(yíng)的各個(gè)環(huán)節(jié)都注重質(zhì)量控制，確保產(chǎn)品符合嚴(yán)格的內(nèi)部標(biāo)準(zhǔn)、國(guó)際標(biāo)準(zhǔn)和行業(yè)標(biāo)準(zhǔn)，以及與醫(yī)療器械有關(guān)的各種法律法規(guī)的詳細(xì)要求，包括但不限于醫(yī)療器械的注冊(cè)和備案、生產(chǎn)經(jīng)營(yíng)許可證、生產(chǎn)和質(zhì)量管理。
治療計(jì)劃軟件市場(chǎng)的特點(diǎn)是產(chǎn)品開(kāi)發(fā)迅速，技術(shù)進(jìn)步，競(jìng)爭(zhēng)激烈，并著重強(qiáng)調(diào)專(zhuān)有產(chǎn)品。在所有產(chǎn)品線(xiàn)和產(chǎn)品層次上，公司在中國(guó)國(guó)內(nèi)和國(guó)際上都面臨著直接競(jìng)爭(zhēng)。價(jià)格、價(jià)值、客戶(hù)支持、品牌識(shí)別、聲譽(yù)、產(chǎn)品功能、可靠性和兼容性等因素是競(jìng)爭(zhēng)中的關(guān)鍵考慮因素。
截至2023年，北京飛天在近距離治療TPS的安裝總量中占有61.2%的市場(chǎng)份額。
我們的使命是提供創(chuàng)新醫(yī)療解決方案和世界一流的服務(wù)，成為醫(yī)院、醫(yī)生和患者可靠的合作伙伴。
|
